Get the Stockscreener App
89.00
0.96%
-0.865
After Hours:
88.96
-0.04
-0.04%
Kymera Therapeutics Inc stock is traded at $89.00, with a volume of 389.98K.
It is down -0.96% in the last 24 hours and up +12.62% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
See More
Previous Close:
$89.86
Open:
$89.55
24h Volume:
389.98K
Relative Volume:
0.54
Market Cap:
$7.27B
Revenue:
$39.21M
Net Income/Loss:
$-311.35M
P/E Ratio:
-24.19
EPS:
-3.6793
Net Cash Flow:
$-234.34M
1W Performance:
+2.15%
1M Performance:
+12.62%
6M Performance:
+41.52%
1Y Performance:
+249.57%
1-Day Range:
$87.73
$90.14
1-Week Range:
$84.19
$90.14
52-Week Range:
$24.43
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
89.00 | 7.34B | 39.21M | -311.35M | -234.34M | -3.6793 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-03-25 | Resumed | Guggenheim | Buy |
| Oct-24-25 | Reiterated | B. Riley Securities | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-18-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jun-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-02-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Kymera Therapeutics (KYMR) to present Phase 1b BroADen trial data for KT-621 at AAD 2026 - MSN
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug - TradingView — Track All Markets
Kymera Therapeutics (KYMR) Receives Fast Track Designation for K - GuruFocus
Kymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven Disorders - Seeking Alpha
RSI Check: What is the earnings history of Kymera Therapeutics IncGap Up & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma - Investing News Network
Kymera Therapeutics (KYMR) Receives Fast Track Designation for KT-621 - GuruFocus
FDA grants fast track status to Kymera’s KT-621 for asthma - Investing.com India
FDA grants fast track status to Kymera’s KT-621 for asthma By Investing.com - Investing.com South Africa
Aug Closing: Can Kymera Therapeutics Inc weather a recession2026 Market Overview & Long-Term Investment Growth Plans - baoquankhu1.vn
Kymera Therapeutics Advances KT-621 with FDA Fast Track Designation for Asthma and Atopic Dermatitis Trials - Quiver Quantitative
FDA Fast Track puts Kymera's once-daily oral asthma drug in focus - Stock Titan
How Investors Are Reacting To Kymera Therapeutics (KYMR) Gilead Option Exercise And US$45M Milestone - Sahm
KYMR SEC FilingsKymera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Gilead expands Tempus AI partnership to boost oncology pipeline - MSN
Discipline and Rules-Based Execution in KYMR Response - Stock Traders Daily
Kymera Therapeutics CBO sells $500k in KYMR stock By Investing.com - Investing.com Australia
Kymera Therapeutics (NASDAQ:KYMR) Insider Noah Goodman Sells 8,264 Shares - MarketBeat
Noah Goodman Sells 2,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Kymera Therapeutics CBO sells $500k in KYMR stock - Investing.com
Kymera Therapeutics (KYMR) CBO trades shares under Rule 10b5-1 plan - Stock Titan
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 - Yahoo Finance
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline - Sahm
Gilead exercises option to license Kymera’s KT-200 - BioWorld News
H.C. Wainwright reiterates Kymera Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - Investing News Network
Kymera Therapeutics (NASDAQ: KYMR) brokered sale notice for 11,611 shares - Stock Titan
Gilead Sciences (GILD) Secures Exclusive Rights to KT-200 from K - GuruFocus
Gilead exercises option on Kymera’s CDK2 degrader for $45M By Investing.com - Investing.com South Africa
Gilead exercises option on Kymera’s CDK2 degrader for $45M - Investing.com
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - The Manila Times
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 ... - Bluefield Daily Telegraph
Gilead picks up oral cancer drug KT-200, triggering $45M payout - Stock Titan
CEO Change: Is now the right time to enter Kymera Therapeutics IncEarnings Growth Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Aug PostEarnings: What is the earnings history of Kymera Therapeutics Inc2026 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout - MSN
SG Americas Securities LLC Grows Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Soars After Multiple Analyst Upgrades; Retail Sentiment Turns Extremely Bullish - MSN
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - AOL.com
Jeremy Chadwick Sells 7,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $1,251,134.40 in Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 4,600 Shares - MarketBeat
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):